56R0 Stock Overview
Through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NanoVibronix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.46 |
| 52 Week High | US$1.21 |
| 52 Week Low | US$0.43 |
| Beta | 1.64 |
| 1 Month Change | 0% |
| 3 Month Change | -7.66% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 56R0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 1.3% |
| 1Y | n/a | -9.7% | 9.0% |
Return vs Industry: Insufficient data to determine how 56R0 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 56R0 performed against the German Market.
Price Volatility
| 56R0 volatility | |
|---|---|
| 56R0 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 56R0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 56R0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 13 | Brian Murphy | www.nanovibronix.com |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.
NanoVibronix, Inc. Fundamentals Summary
| 56R0 fundamental statistics | |
|---|---|
| Market cap | €1.99m |
| Earnings (TTM) | -€3.00m |
| Revenue (TTM) | €3.20m |
0.6x
P/S Ratio-0.7x
P/E RatioIs 56R0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 56R0 income statement (TTM) | |
|---|---|
| Revenue | US$3.29m |
| Cost of Revenue | US$1.33m |
| Gross Profit | US$1.96m |
| Other Expenses | US$5.05m |
| Earnings | -US$3.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.82 |
| Gross Margin | 59.62% |
| Net Profit Margin | -93.80% |
| Debt/Equity Ratio | 0% |
How did 56R0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 06:22 |
| End of Day Share Price | 2024/10/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NanoVibronix, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Dawson James Securities |
| Joseph Gomes | Wm Smith & Co. |
| Brian Marckx | Zacks Investment Research Inc. |